819 related articles for article (PubMed ID: 7251238)
1. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
2. Absorption of sustained-release theophylline tablets.
Fagerström PO; Heintz L
Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
[TBL] [Abstract][Full Text] [Related]
3. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
4. [Bioavailability of a delayed-action aminophylline preparation].
Regazzi MB; Guarnone E; Bartoli A; Ciardelli L; Piacentini P
Minerva Med; 1985 Mar; 76(13):641-5. PubMed ID: 3991030
[TBL] [Abstract][Full Text] [Related]
5. Comparison of steady state serum theophylline concentrations in healthy volunteers after dosing with Euphyllin retard and PulmiDur.
Karlsson S; Lührmann B; Bahner ML; Schulz HU
Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):342-6. PubMed ID: 3623739
[TBL] [Abstract][Full Text] [Related]
6. Absorption of theophylline from conventional and sustained-release tablets.
Fagerström PO; Mellstrand T; Svedmyr N
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
[TBL] [Abstract][Full Text] [Related]
7. Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing.
Schulz HU; Steinijans VW; Gabel H
Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):621-5. PubMed ID: 6500759
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of a new sustained-release theophylline preparation.
Dahlqvist R; Billing B
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
[TBL] [Abstract][Full Text] [Related]
9. Absorption of theophylline from conventional and sustained-release tablets.
Mellstrand T; Svedmyr N; Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
[TBL] [Abstract][Full Text] [Related]
10. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
[TBL] [Abstract][Full Text] [Related]
11. The relation of product formulation to absorption of oral theophylline.
Weinberger M; Hendeles L; Bighley L
N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of sustained-release theophylline formulations.
Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
Bochsler HP; Meyer UA
Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of sustained release and conventional tablets of theophylline plus hydroxyethyltheophylline and its comparison with tablet aminophylline.
Gupta S; Raina RK; Samotra K; Gupta KL
Indian J Chest Dis Allied Sci; 1991; 33(1):1-8. PubMed ID: 1791015
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
van der Vet AP; Drost RH; Kreukniet J; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
17. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of Theodel, a new theophylline tablet, in humans.
Rovei V; Strolin Benedetti M; Donath A; Grenot C; Chanoine F
Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):425-30. PubMed ID: 6629546
[TBL] [Abstract][Full Text] [Related]
19. Theophylline bioavailability following oral administration of six sustained-release preparations.
Spangler DL; Kalof DD; Bloom FL; Wittig HJ
Ann Allergy; 1978 Jan; 40(1):6-11. PubMed ID: 623398
[TBL] [Abstract][Full Text] [Related]
20. [Absolute bioavailability of theophylline (Euphylline)].
Somogyi A; Gugler R
Fortschr Med; 1980 Nov; 98(43):1707-10. PubMed ID: 7450653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]